BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 30327172)

  • 41. Expression of telomerase reverse transcriptase in peripheral T-cell lymphoma.
    Arakawa F; Miyoshi H; Yoshida N; Nakashima K; Watatani Y; Furuta T; Yamada K; Moritsubo M; Takeuchi M; Yanagida E; Shimasaki Y; Kohno K; Kataoka K; Ohshima K
    Cancer Med; 2021 Oct; 10(19):6786-6794. PubMed ID: 34477310
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Expressions of CXCL13, CD10 and bcl-6 in angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma, not otherwise specified].
    Tang XF; Li GD; Li YL; Liang DN; Xia T; Zhou JY; Yao YQ; Wu WQ; Wang ZG; Yang YH; Tang XB; Bai YQ; Ding Q
    Zhonghua Bing Li Xue Za Zhi; 2009 Apr; 38(4):224-30. PubMed ID: 19575892
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparison of clinicopathological characteristics between T-cell prolymphocytic leukemia and peripheral T-cell lymphoma, not otherwise specified.
    Kawamoto K; Miyoshi H; Yanagida E; Yoshida N; Kiyasu J; Kozai Y; Morikita T; Kato T; Suzushima H; Tamura S; Muta T; Kato K; Eto T; Seki R; Nagafuji K; Sone H; Takizawa J; Seto M; Ohshima K
    Eur J Haematol; 2017 May; 98(5):459-466. PubMed ID: 28129454
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Treatment of Peripheral T-Cell Lymphoma in Community Settings.
    Feldman T; Farber CM; Choi K; Faria C; Goy A; Connors J; Paramanathan D; Kaur S; Schultz E; McGuire M; Goldberg SL
    Clin Lymphoma Myeloma Leuk; 2017 Jun; 17(6):354-361. PubMed ID: 28622960
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma.
    Shi Y; Dong M; Hong X; Zhang W; Feng J; Zhu J; Yu L; Ke X; Huang H; Shen Z; Fan Y; Li W; Zhao X; Qi J; Huang H; Zhou D; Ning Z; Lu X
    Ann Oncol; 2015 Aug; 26(8):1766-71. PubMed ID: 26105599
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Soluble programmed death-ligand 1 are highly expressed in peripheral T-cell lymphoma: a biomarker for prognosis.
    Shen H; Ji Y; Zhou D; Zhang Y; Wang W; Sun J; Zhang W
    Hematology; 2019 Dec; 24(1):392-398. PubMed ID: 30890046
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparative analysis of extra-nodal NK/T-cell lymphoma and peripheral T-cell lymphoma: significant differences in clinical characteristics and prognosis.
    Lim ST; Hee SW; Quek R; Lim LC; Yap SP; Loong EL; Sng I; Tan LH; Ang MK; Ngeow J; Tham CK; Ngo L; Tan MH; Tao M
    Eur J Haematol; 2008 Jan; 80(1):55-60. PubMed ID: 18028433
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Long-term outcome of patients with peripheral T-cell lymphoma treated with first-line intensive chemotherapy followed by autologous stem cell transplantation.
    Prochazka V; Faber E; Raida L; Papajik T; Vondrakova J; Rusinakova Z; Kucerova L; Myslivecek M; Indrak K
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2011 Mar; 155(1):63-9. PubMed ID: 21475380
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Combination of 13-cis retinoic acid and interferon-alpha in the treatment of recurrent or refractory peripheral T-cell lymphoma.
    Huang CL; Lin ZZ; Su IJ; Chao TY; Tien HF; Chang MC; Huang MC; Kao WY; Tang JL; Yeh KH; Wang CH; Hsu CH; Liu MY; Cheng AL
    Leuk Lymphoma; 2002 Jul; 43(7):1415-20. PubMed ID: 12389622
    [TBL] [Abstract][Full Text] [Related]  

  • 50. High intratumoural galectin-1 expression predicts adverse outcome in ALK
    Holst JM; Ludvigsen M; Hamilton-Dutoit SJ; Bendix K; Plesner TL; Nørgaard P; Møller MB; Steiniche T; Rabinovich GA; d'Amore F; Pedersen MB
    Hematol Oncol; 2020 Feb; 38(1):59-66. PubMed ID: 31834627
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Expression of follicular helper T cell markers in nodal peripheral T cell lymphomas: a tissue microarray analysis of 162 cases.
    Zhan HQ; Li XQ; Zhu XZ; Lu HF; Zhou XY; Chen Y
    J Clin Pathol; 2011 Apr; 64(4):319-24. PubMed ID: 21330314
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The aggressive peripheral T-cell lymphomas: 2015.
    Armitage JO
    Am J Hematol; 2015 Jul; 90(7):665-73. PubMed ID: 26031230
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Absolute monocyte count is a predictor of overall survival and progression-free survival in nodal peripheral T cell lymphoma.
    de Pádua Covas Lage LA; Hamasaki DT; Moreira FR; Rocha V; Zerbini MCN; Pereira J
    Ann Hematol; 2019 Sep; 98(9):2097-2102. PubMed ID: 31243570
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparison of prognostic scores in transplant-ineligible patients with peripheral T-cell lymphoma not otherwise specified and angioimmunoblastic T-cell lymphoma: a retrospective study from the national hospital organization in Japan.
    Yamasaki S; Iida H; Yoshida I; Komeno T; Sawamura M; Matsumoto M; Sekiguchi N; Hishita T; Sunami K; Shimomura T; Takatsuki H; Yoshida S; Otsuka M; Kato T; Kuroda Y; Ooyama T; Suzuki Y; Ohshima K; Nagai H; Iwasaki H
    Leuk Lymphoma; 2021 Apr; 62(4):819-827. PubMed ID: 33167741
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Impact of primary organ site of involvement by peripheral T-cell lymphoma not otherwise specified on survival.
    Davis O; Truong D; Day S; Pandey M; Ibrahimi S; Khawandanah M; Holter-Chakrabarty J; Asch A; Al-Juhaishi T
    Cancer Med; 2023 Dec; 12(24):21770-21778. PubMed ID: 38073461
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clinical significance of enhancer of zeste homolog 2 and histone deacetylases 1 and 2 expression in peripheral T-cell lymphoma.
    Zhang H; Lv H; Jia X; Hu G; Kong L; Zhang T; Li L; Pan Y; Zhai Q; Meng B; Wang X; Wang H; Wang X
    Oncol Lett; 2019 Aug; 18(2):1415-1423. PubMed ID: 31423206
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Phase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides: SWOG 1108.
    Barr PM; Li H; Spier C; Mahadevan D; LeBlanc M; Ul Haq M; Huber BD; Flowers CR; Wagner-Johnston ND; Horwitz SM; Fisher RI; Cheson BD; Smith SM; Kahl BS; Bartlett NL; Friedberg JW
    J Clin Oncol; 2015 Jul; 33(21):2399-404. PubMed ID: 26077240
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Genomics of Peripheral T-Cell Lymphoma and Its Implications for Personalized Medicine.
    Zhang Y; Lee D; Brimer T; Hussaini M; Sokol L
    Front Oncol; 2020; 10():898. PubMed ID: 32637355
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Increased incidence of adult T cell leukemia-lymphoma and peripheral T cell lymphoma-not otherwise specified with limited improvement in overall survival: a retrospective analysis using data from the population-based Osaka Cancer Registry.
    Fuji S; Kida S; Nakata K; Morishima T; Miyashiro I; Ishikawa J
    Ann Hematol; 2021 Jan; 100(1):157-165. PubMed ID: 33089366
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prognostic value of baseline total metabolic tumor volume (TMTV0) measured on FDG-PET/CT in patients with peripheral T-cell lymphoma (PTCL).
    Cottereau AS; Becker S; Broussais F; Casasnovas O; Kanoun S; Roques M; Charrier N; Bertrand S; Delarue R; Bonnet C; Hustinx R; Gaulard P; de Leval L; Vera P; Itti E; Mounier N; Haioun C; Tilly H; Meignan M
    Ann Oncol; 2016 Apr; 27(4):719-24. PubMed ID: 26787236
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.